BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Questcor Pharmaceuticals, Inc. (Headquarters) (QSC) Takes a Blow After Aetna Cuts Reimbursement Coverage


9/20/2012 7:54:03 AM

America's third-largest health insurer, Aetna Inc (AET.N), said it would no longer reimburse Questcor Pharmaceutical's (QCOR.O) sole drug for most diseases, wiping off more than $1 billion of the drugmaker's market value. In a clinical policy bulletin published on its website on Wednesday, Aetna said Questcor's Acthar gel was medically necessary only to treat infantile spasms as the drug was no better than existing therapies in the 18 other diseases that it was approved to treat. Shares of Anaheim, California-based Questcor fell as much as 56 percent, before regaining some losses to trade down 40 percent at $30.37 Wednesday afternoon on the Nasdaq.

Read at Reuters
Read at BusinessWeek
Read at Market Watch
Read at Barron's Online
Read at Wall Street Journal

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->